Introduction {#Sec1}
============

Obesity is a chronic disease with a globally rising rate that reached 30.1% in 2017 \[[@CR1]\]. Metabolic and bariatric surgery has been proved to be the most effective method not only for weight loss \[[@CR2], [@CR3]\] but also for resolving or improving associated comorbidities \[[@CR4]--[@CR7]\] and quality of life as well as long-term mortality in obese patients \[[@CR8]\].

Although the obesity rate has had an upward trend in almost all racial groups, some races are disproportionately affected. Based on the Centers for Disease Control (CDC) reports, Asian adults had the lowest obesity prevalence in 2017 while non-Hispanic black adults (39%) had the highest, followed by American Indian/Alaska Native (38.7%), Hispanic (32.4%), and non-Hispanic White adults (29.3%) \[[@CR1]\]. Among proposed etiologies for this disproportionate distribution are socio-economic factors and their effects on nutrition \[[@CR9]\], genetic differences \[[@CR10]\], and possible ethnic differences in fat metabolism \[[@CR11]\]. Additionally, there is evidence of gender disparity with female dominance \[[@CR12]\] and unequal utilization of bariatric surgery with fewer African Americans undergoing these procedures compared with Whites \[[@CR13]\] despite a higher obesity rate in the former. Furthermore, there is evidence of disparate long-term response to bariatric procedures especially disproportionate success in weight loss among different races \[[@CR14]--[@CR16]\].

While there are numerous studies on these aspects of disparity in metabolic and bariatric surgery especially related to long-term outcomes, there has been limited evaluation of the impact of race on the short-term postoperative outcomes of these procedures, which constitutes the primary aim of this study.

Methods {#Sec2}
=======

Data Source {#Sec3}
-----------

Data were obtained from the 2016 Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) participant use files (PUF) including cases with operation dates between January 1, 2016, and December 31, 2016. With over 790 participating sites across the USA and Canada, the MBSAQIP data registry is the largest bariatric-specific dataset containing preoperative, intraoperative, and postoperative data for patients undergoing metabolic and bariatric surgery. All data are collected by trained and certified metabolic and bariatric surgical clinical reviewers (MBSCRs), and selected participating centers are regularly audited to ensure the data collected are of the highest quality \[[@CR17]\].

Study Population {#Sec4}
----------------

This study included patients with age ≥ 18 years and BMI ≥ 35 who underwent either laparoscopic Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG), the two most commonly performed bariatric procedures. We used the current procedural terminology (CPT) for the principal operative procedure selection: LRYGB (43644, 43645), LSG (43775). We excluded those with unknown race or ethnicity information, previous bariatric surgery, revisional or conversional cases, emergency cases, and any surgical approach other than conventional laparoscopic approach.

Outcomes {#Sec5}
--------

The outcomes of interest were 30-day postoperative outcomes including composite "postoperative complication" defined as presence of any of the 24 adverse events: superficial incisional surgical site infection (SSI), deep incisional SSI, organ/space SSI, wound disruption, sepsis, septic shock, urinary tract infection (UTI), acute renal failure (ARF), progressive renal insufficiency, mechanical ventilation \> 48 h, unplanned intubation, pneumonia, unplanned admission to ICU, deep venous thrombosis (DVT), pulmonary embolism (PE), cardiac arrest, myocardial infarction (MI), stroke, coma \> 24 h, peripheral nerve injury, Clostridium difficile colitis, dehydration requiring treatment, incisional hernia, and presence of operative drain at 30 days. Other 30-day postoperative outcomes considered as endpoints were at least one readmission, re-intervention, and reoperation.

Statistical Analysis {#Sec6}
--------------------

Five different races (White, Black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or other Pacific Islander) were compared for basic characteristics and comorbidities, perioperative factors, and postoperative outcomes using chi-square or Fisher's exact tests for categorical variables and analysis of variance (ANOVA) for continuous variables. Multivariate logistic regression models were used to examine the effect of race on outcomes and included patient characteristics, comorbidities, and perioperative factors with *p* \< 0.05 found in univariate analyses for each outcome. Odds ratios (OR) along with 95% confidence intervals (CI) were reported, and inference was based on a two-sided 5% level. The analysis was performed using SPSS (Version 22, Chicago, IL).

Results {#Sec7}
=======

The study cohort consisted of 106,932 patients who underwent LRYGB or LSG. The majority were White (79.5%) followed by Black or African American (AA) (19.3%), Asian (0.5%), American Indian or Alaska Native (0.4%), and Native Hawaiian or other Pacific Islanders (0.3%). Table [1](#Tab1){ref-type="table"} demonstrates the baseline characteristics in these five groups, most of which are different in at least two of the racial groups. The majority of patients were females who underwent LSG, with a significant gap between the two procedures, except in Native Hawaiian or other Pacific Islander, in which case, the gap became closer. AA and Native Hawaiian or other Pacific Islander patients had significantly higher BMI in comparison with Whites. Additionally, AA patients tended to smoke less within 1 year of surgery when compared with Whites, while American Indian or Alaska Natives had the highest percentage of smokers (13%) among others. There were also significantly more patients with American Society of Anesthesiologists (ASA) class \> 2 among AAs and Native Hawaiian or other Pacific Islanders when compared with Whites.Table 1Patient characteristicsCovariatesTotal\
*N* = 106,932 (%) or mean ± SDWhite\
*N* = 85,054 (79.5%)Black or African American\
*N* = 20,629 (19.3%)Asian\
*N* = 532 (0.5%)American Indian or Alaska Native\
*N* = 377 (0.4%)Native Hawaiian or other Pacific Islanders\
*N* = 340 (0.3%)*p* valueAge (years)44.65 ± 11.8945.16 ± 12.0842.69 ± 10.9142.23 ± 10.8643.23 ± 11.0142.2 ± 10.78*\< 0.001*Gender (female)84,693 (79.2)66,026 (77.6)17,715 (85.9)384 (72.2)314 (83.3)254 (74.7)*\< 0.001*Pre-op weight closest to bariatric surgery (Ibs)241.36 ± 85.29239.95 ± 84.35248.4 ± 88.49215.25 ± 83.41226.41 ± 88.2223.88 ± 93.34*\< 0.001*Pre-op BMI closest to bariatric surgery45.78 ± 7.6145.41 ± 7.3847.33 ± 8.344.24 ± 7.645.68 ± 7.2647.37 ± 8.68*\< 0.001*BMI ≥ 5025,395 (23.7)18,834 (22.1)6272 (30.4)94 (17.7)95 (25.2)100 (29.4)*\< 0.001*Current smoker within 1 year9495 (8.9)7748 (9.1)1614 (7.8)47 (8.8)49 (13)37 (10.9)*\< 0.001*Dependent pre-op functional health status1120 (1)857 (1)246 (1.2)8 (1.5)5 (1.3)4 (1.2)0.141Limited pre-op ambulation1701 (1.6)1331 (1.6)349 (1.7)7 (1.3)7 (1.9)7 (2.1)0.625Pre-op albumin lab value2.96 ± 1.822.99 ± 1.822.86 ± 1.792.85 ± 1.912.85 ± 1.853.17 ± 1.81*\< 0.001*Pre-op hematocrit lab value36.44 ± 13.2336.78 ± 13.4435.03 ± 12.1836.99 ± 13.3435.8 ± 14.337.16 ± 12.93*\< 0.001*ASA class*\< 0.001*Class 1290 (0.3)241 (0.3)49 (0.2)000Class 223,035 (21.5)18,703 (22)4087 (19.8)112 (21.1)86 (22.8)47 (13.8)Class 379,490 (74.3)62,901 (74)15,637 (75.8)401 (75.4)277 (73.5)274 (80.6)Class 43359 (3.1)2557 (3)756 (3.7)17 (3.2)13 (3.4)16 (4.7)Principle operative procedure*\< 0.001*LSG77,392 (72.4)60,506 (71.1)16,068 (77.9)379 (71.2)253 (67.1)186 (54.7)LRYGB29,540 (27.6)24,548 (28.9)4561 (22.1)153 (28.8)124 (32.9)154 (45.3)*BMI* body mass index, *ASA* American Society of Anesthesiologists, *LSG* laparoscopic sleeve gastrectomy, *LRYGB* laparoscopic Roux-en-y gastric bypass

Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and [4](#Tab4){ref-type="table"} highlight the comorbidities, peri- and postoperative outcomes between racial groups. All comparisons are made with White patients as the reference. AAs had higher rates of hypertension, inferior vena cava (IVC) filter in anticipation of the surgery, renal insufficiency, and requiring or being on dialysis, while lower rates of most other comorbidities. Asian patients had higher rates of diabetes (33.5%) and obstructive sleep apnea (44.4%). American Indian or Alaska Native and Native Hawaiian or other Pacific Islander also had higher rates of diabetes and renal insufficiency (Table [2](#Tab2){ref-type="table"}). Regarding the perioperative factors, there were some technical differences among racial groups as well as difference in operation length, which was significantly higher in AAs (Table [3](#Tab3){ref-type="table"}).Table 2ComorbiditiesCovariatesTotal\
*N* = 106,932White\
*N* = 85,054 (79.5%)Black or African American\
*N* = 20,629 (19.3%)Asian\
*N* = 532 (0.5%)American Indian or Alaska Native\
*N* = 377 (0.4%)Native Hawaiian or other Pacific Islanders\
*N* = 340 (0.3%)*p* valueDiabetes28,128 (26.3)22,317 (26.2)5384 (26.1)178 (33.5)135 (35.8)114 (33.5)*\< 0.001*Hypertensive requiring medication52,399 (49)40,780 (47.9)11,050 (53.6)243 (45.7)170 (45.1)156 (45.9)*\< 0.001*Hyperlipidemia25,920 (24.2)21,612 (25.4)3993 (19.4)138 (25.9)104 (27.6)73 (21.5)*\< 0.001*GERD requiring medication33,892 (31.7)28,349 (33.3)5244 (25.4)118 (22.2)126 (33.4)55 (16.2)*\< 0.001*OSA420.82 (39.4)34,172 (40.2)7367 (35.7)236 (44.4)165 (43.8)142 (41.8)*\< 0.001*COPD1956 (1.8)1640 (1.9)302 (1.5)4 (0.8)9 (2.4)1 (0.3)*\< 0.001*Oxygen dependent799 (0.7)692 (0.8)104 (0.5)02 (0.5)1 (0.3)*\< 0.001*MI1497 (1.4)1266 (1.5)217 (1.1)6 (1.1)2 (0.5)6 (1.8)*\< 0.001*PCI/PTCA2406 (2.3)2072 (2.4)314 (1.5)11 (2.1)2 (0.5)7 (2.1)*\< 0.001*Previous cardiac surgery1280 (1.2)1079 (1.3)190 (0.9)6 (1.1)3 (0.8)2 (0.6)*0.001*DVT1763 (1.6)1419 (1.7)331 (1.6)2 (0.4)6 (1.6)5 (1.5)0.211PE1321 (1.2)1021 (1.2)287 (1.4)3 (0.6)6 (1.6)4 (1.2)0.12Venous stasis1314 (1.2)1148 (1.3)147 (0.7)6 (1.1)6 (1.6)7 (2.1)*\< 0.001*IVC filter859 (0.8)510 (0.6)347 (1.7)1 (0.2)1 (0.3)0*\< 0.001*IVC filter timing*\< 0.001*In anticipation of the metabolic or bariatric procedure591/859 (68.8)309/510 (60.6)281/347 (81)1 (100)00Pre-existing259/859 (30.2)196/510 (38.4)62/347 (17.9)01 (100)0Pre-op therapeutic anticoagulation2910 (2.7)2429 (2.9)455 (2.2)10 (1.9)8 (2.1)8 (2.4)*\< 0.001*Renal insufficiency704 (0.7)439 (0.5)250 (1.2)3 (0.6)7 (1.9)5 (1.5)*\< 0.001*Requiring or on dialysis306 (0.3)161 (0.2)139 (0.7)3 (0.6)1 (0.3)2 (0.6)*\< 0.001*Steroid/immunosuppressant use for chronic condition1868 (1.7)1462 (1.7)379 (1.8)10 (1.9)10 (2.7)7 (2.1)0.491At least one comorbidity82,750 (77.4)66,049 (77.7)15,739 (76.3)417 (78.4)297 (78.8)248 (72.9)*\< 0.001GERD* gastroesophageal reflux disease, *OSA* obstructive sleep apnea, *COPD* chronic obstructive pulmonary disease, *MI* myocardial infarction, *PCI/PTCA* percutaneous coronary intervention/percutaneous transluminal coronary angioplasty, *DVT* deep venous thrombosis, *PE* pulmonary embolism, *IVC* inferior vena cavaTable 3Perioperative factorsCovariatesTotal\
*N* = 106,932\
*N* (%) or mean ± SDWhite\
*N* = 85,054 (79.5%)Black or African American\
*N* = 20,629 (19.3%)Asian\
*N* = 532 (0.5%)American Indian or Alaska Native\
*N* = 377 (0.4%)Native Hawaiian or other Pacific Islanders\
*N* = 340 (0.3%)*p* valueSleeve staple line reinforcement52,829 (49.4)41,094 (48.3)11,216 (54.4)242 (45.5)166 (44)111 (32.6)*\< 0.001*Sleeve oversew17,226 (16.1)13,408 (15.8)3657 (17.7)73 (13.7)47 (12.5)41 (12.2)*\< 0.001*Sleeve bougie size \> 38 F23,416 (21.9)17,862 (21)5329 (25.8)112 (21.1)81 (21.5)32 (9.4)*\< 0.001*Sleeve distance to pylorus \> 4 cm48,931 (45.8)38,135 (44.8)10,270 (49.8)234 (44)192 (50.9)100 (29.4)*\< 0.001*Drain placed at the time of the initial operation21,499 (20.1)17,218 (20.2)4066 (19.7)110 (20.7)47 (12.5)58 (17.1)*0.001*Anastomosis/staple line checked w/provocative test to assess for leak83,462 (78.1)66,436 (78.1)16,048 (77.8)393 (73.9)289 (76.7)296 (87.1)*\< 0.001*Swallow study performed day of or day after procedure38,018 (35.6)29,312 (34.5)8354 (40.5)162 (30.5)104 (27.6)86 (25.3)*\< 0.001*Transfusion intra-op/post-op (72 h of surgery start time)658 (0.6)519 (0.6)130 (0.6)5 (0.9)3 (0.8)1 (0.3)0.772Superficial incisional SSI PATOS3 (0.0)3 (0.0)00000.942Deep incisional SSI PATOS4 (0.0)4 (0.0)00000.905Organ/space SSI PATOS5 (0.0)3 (0.0)2 (0.0)0000.842Pneumonia PATOS6 (0.0)3 (0.0)3 (0.0)0000.454Ventilator \> 48 h PATOS1 (0.0)01 (0.0)0000.382UTI PATOS26 (0.0)18 (0.0)8 (0.0)0000.658Sepsis PATOS7 (0.0)6 (0.0)1 (0.0)0000.995Operation length (min)83.42 ± 45.882.78 ± 45.485.97 ± 47.284.18 ± 44.383.45 ± 44.989.32 ± 48.1*\< 0.001SSI* surgical site infection, *PATOS* present at the time of surgeryTable 4Postoperative outcomes and complicationsCovariatesTotal\
*N* = 106,932\
*N* (%) or mean ± SDWhite\
*N* = 85,054 (79.5%)Black or African American\
*N* = 20,629 (19.3%)Asian\
*N* = 532 (0.5%)American Indian or Alaska Native\
*N* = 377 (0.4%)Native Hawaiian or other Pacific Islanders\
*N* = 340 (0.3%)*p* valuePost-op superficial incisional SSI475 (0.4)404 (0.5)59 (0.3)3 (0.6)2 (0.5)7 (2.1)*\< 0.001*Post-op deep incisional SSI64 (0.1)54 (0.1)9 (0.0)01 (0.3)00.37Post-op organ/space SSI183 (0.2)154 (0.2)26 (0.1)1 (0.2)1 (0.3)1 (0.3)0.485Wound disruption58 (0.1)40 (0.0)15 (0.1)2 (0.4)01 (0.3)*0.003*Post-op sepsis96 (0.1)83 (0.1)11 (0.1)01 (0.3)1 (0.3)0.136Post-op septic shock56 (0.1)45 (0.1)10 (0.0)001 (0.3)0.362Post-op UTI391 (0.4)316 (0.4)65 (0.3)6 (1.1)2 (0.5)2 (0.6)*0.029*Acute renal failure71 (0.1)54 (0.1)16 (0.1)1 (0.2)000.7Progressive renal insufficiency57 (0.1)40 (0.0)16 (0.1)01 (0.3)00.162On ventilator \> 48 h72 (0.1)60 (0.1)12 (0.1)0000.873Unplanned intubation167 (0.2)130 (0.2)35 (0.2)1 (0.2)1 (0.3)00.885Post-op pneumonia232 (0.2)192 (0.2)39 (0.2)1 (0.2)000.622Unplanned admission to ICU within 30 Days708 (0.7)539 (0.6)160 (0.8)4 (0.8)2 (0.5)3 (0.9)0.24Post-op vein thrombosis requiring therapy191 (0.2)143 (0.2)47 (0.2)1 (0.2)000.329Pulmonary embolism121 (0.1)81 (0.1)38 (0.2)1 (0.2)1 (0.3)0*0.011*Intra-op or post-op cardiac arrest requiring CPR33 (0.0)28 (0.0)5 (0.0)0000.939Intra-op or post-op MI38 (0.0)32 (0.0)4 (0.0)2 (0.4)00*0.001*Stroke/CVA11 (0.0)8 (0.0)3 (0.0)0000.968Coma \> 24 h4 (0.0)2 (0.0)2 (0.0)0000.655Clostridium difficile colitis163 (0.2)138 (0.2)24 (0.1)01 (0.3)00.413Patient received treatment for dehydration3956 (3.7)2928 (3.4)987 (4.8)9 (1.7)21 (5.6)11 (3.2)*\< 0.001*Incisional hernia noted on exam81 (0.1)61 (0.1)19 (0.1)001 (0.3)0.442Operative drain still present at 30 days322 (0.3)254 (0.3)67 (0.3)001 (0.3)0.533Death during operation (intra-op death) or post-op death within 30 days of procedure91 (0.1)69 (0.1)21 (0.1)1 (0.2)000.716Death likely related to the operation41/91 (45.05)29/69 (42)12/21 (57.1)0000.314Most likely cause of death0.294Other respiratory failures15/91 (16.48)114------PE12/91 (13.18)57------Pneumonia4/91 (4.39)4--------Bleeding3/91 (3.29)3--------Vein thrombosis requiring therapy2/91 (2.19)--2------Anastomotic/staple line leak1/91 (1.09)1--------Fluid, electrolyte, or nutritional depletion1/91 (1.09)1--------GI perforation1/91 (1.09)1--------Other abdominal sepsis1/91 (1.09)1--------Other51/91 (56.04)4281----Days to discharge form hospital admit1.7 ± 1.181.67 ± 1.131.81 ± 1.331.75 ± 1.51.79 ± 1.441.59 ± 0.7*\< 0.001*Discharge destination other than home545 (0.5)379 (0.4)159 (0.8)4 (0.8)2 (0.5)1 (0.3)*\< 0.001*Days to post-op assessment from operation14.12 ± 7.514.13 ± 7.514.06 ± 7.514.32 ± 7.715.12 ± 7.814.5 ± 8.050.059Patient was seen in any ED which did not result in an inpatient admission6668 (6.2)4965 (5.8)1618 (7.8)26 (4.9)33 (8.8)26 (7.6)*\< 0.001*At least one post-op complication6460 (6)4921 (5.8)1458 (7.1)26 (4.9)30 (8)25 (7.4)*\< 0.001*At least one readmission within 30 days of op4107 (3.8)2997 (3.5)1067 (5.2)17 (3.2)16 (4.2)10 (2.9)*\< 0.001*At least one intervention within 30 days of op1393 (1.3)1005 (1.2)366 (1.8)6 (1.1)10 (2.7)6 (1.8)*\< 0.001*At least one reoperation within 30 days of op1256 (1.2)980 (1.2)259 (1.3)7 (1.3)5 (1.3)5 (1.5)0.744*UTI* urinary tract infection, *ICU* intensive care unit, *CPR* cardiopulmonary resuscitation, *CVA* cerebrovascular accident, *ED* emergency department

With regards to postoperative complications, AAs had significantly higher rates of PE and also longer length of stay, while Asian patients had higher wound disruption, UTI, and MI. Native Hawaiian or other Pacific Islanders, on the other hand, had similar postoperative outcomes to White patients except higher superficial incisional SSI (Table [4](#Tab4){ref-type="table"}).

Although the reoperation rate was not significantly different between groups in the beginning, it was significantly lower in the AA group (OR = 0.831, 95% CI 0.7--0.9) after adjusting for other factors. AA was also the only group, which significantly increased the odds of any postoperative complication (OR = 1.134, 95% CI 1.064--1.209) and readmission (OR = 1.477, 95% CI 1.358--1.606). For the 30-day postoperative intervention, American Indian or Alaska Native as well as AA were the two groups that increased the odds of this event in the adjusted analyses (Table [5](#Tab5){ref-type="table"}).Table 5Racial disparity in four 30-day postoperative outcomes30-day perioperative outcomesAdjusted *p* valueOdds ratio (OR)95% confidence interval (CI)Postoperative complicationsBlack or African American*\< 0.001*1.1341.064--1.209Asian0.2360.7810.519--1.176American Indian or Alaska Native0.2011.2860.874--1.893Native Hawaiian or other Pacific Islanders0.2111.3010.861--1.966ReadmissionBlack or African American*\< 0.001*1.4771.358--1.606Asian0.9040.9670.562--1.666American Indian or Alaska Native0.6540.870.474--1.597Native Hawaiian or other Pacific Islanders0.120.5390.247--1.175Re-interventionBlack or African American*\< 0.001*1.3191.151--1.512Asian0.8511.0850.463--2.541American Indian or Alaska Native**0.04**2.1181.033--4.343Native Hawaiian or other Pacific Islanders0.4651.4030.565--3.487ReoperationBlack or African American*0.023*0.8310.709--0.974Asian0.9281.0420.424--2.56American Indian or Alaska Native0.5120.7030.246--2.014Native Hawaiian or other Pacific Islanders0.4491.4550.551--3.842

Discussion {#Sec8}
==========

We demonstrated racial disparity in four short-term postoperative outcomes after LRYGB and LSG using the largest available bariatric-specific database. Race was an independent risk factor for 30-day postoperative complications, readmission, and re-intervention, and African Americans had higher odds for all of these outcomes with exception of reoperation, in which they had a lower odds compared with Whites. In addition, re-intervention was significantly higher in American Indian or Alaska Natives when Whites considered as the reference group.

In this study, re-interventions were related to the metabolic and bariatric procedure in 88% of cases. Nausea and vomiting, fluid, electrolyte, or nutritional depletion was the most common etiology in all races except in Asians. Additionally, diagnostic and therapeutic endoscopies were most common types of intervention performed in all racial groups. Similar to re-intervention, majority of reoperations were related to the bariatric procedure (77%). Bleeding was the primary reason, and although reoperation type significantly varied among different races, re-exploration (not otherwise qualified) was the most common type in all groups.

Sheka and colleagues \[[@CR18]\] have recently performed a similar study on MBSAQIP 2015. However, they only compared Black and White groups. They further classified the study population based on the principal procedure (LRYGB, LSG) and reported significantly longer length of stay and higher readmission rates in Black patients with both procedures. However, reoperation and re-intervention were significantly higher only in Black patients who underwent SG. They additionally showed significantly higher mortality rate in Black patients who had SG. Although race and specifically non-Hispanic Black race has been reported as an independent predictor of mortality \[[@CR19]\], the mortality rate in this study was 0.1% and we did not find any significant difference in this variable among racial groups in our study population. Additionally, we also observed significantly longer length of stay in African Americans in this study (Table [4](#Tab4){ref-type="table"}), a disparity that has been reported in other fields of surgery as well, and one that Wahl et al. \[[@CR20]\] successfully eliminated in a study between Black and White patients undergoing colorectal surgery with enhanced recovery after surgery protocols.

Tiwari and colleagues \[[@CR21]\] have also used a database with more than 37,000 patients who underwent laparoscopic gastric bypass over 4 years and reported race as a risk factor affecting postoperative outcomes in these patients. They also reported that a 30-day readmission was significantly higher in non-Hispanic Blacks compared with non-Hispanic Whites. African American race has been reported as an independent risk factor for readmission in many other studies as well \[[@CR22]--[@CR24]\]. In this study, the majority of readmissions (78%) were associated with the metabolic and bariatric procedure. Despite significant differences in cause of readmission among racial groups, nausea and vomiting, fluid, electrolyte, or nutritional depletion was the most common cause in all groups and the reason for almost one-fourth of all interventions after the primary procedure.

Postoperative complications were not listed separately in the multivariate logistic regression for each outcome model in order to reduce the number of variables and increase the accuracy of the analysis. However, we found results in univariate analyses that are comparable with previous studies. For instance, occurrence of PE was 1.93 times higher in AAs compared with Whites in our study, which may be secondary to a biological predilection, although this is unknown, and is especially puzzling since there were no significant differences in the preoperative rates of venous thromboembolism. This is comparable with the results of a study by Turner and colleagues \[[@CR25]\] using the National Surgical Quality Improvement Program (NSQIP) database from 2005 to 2007 and reported increased rates of certain postoperative complications including 2.5 times higher PE in African American patients. Venous thrombosis was the third most common reason for readmission in AA patients in this study. Notably, preoperative IVC filter was significantly higher in AAs compared with White patients, while the preoperative rates of DVT or PE were not different between these two racial groups. However, over 80% of AAs who had IVC filter preoperatively received it in anticipation of the bariatric procedure as opposed to a pre-existing filter (18%). These findings are not easily explained. The higher mean preoperative BMI in the AA group and possibly anticipated longer operation times could perhaps account for the significantly higher rates of preoperative IVC filter placement in AAs compared with Whites even though the preoperative PE and DVT rates were similar between the groups.

In addition to postoperative outcomes, there were some differences in the patient characteristics, comorbidities, and perioperative factors (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, and [3](#Tab3){ref-type="table"}) among different races that were adjusted for in the multivariate logistic regression. For instance, despite LSG being the most common procedure performed in all racial groups, LRYGB was performed with even lower rates in AAs compared with Whites, which is similar to what was reported by Worni and colleagues \[[@CR26]\] on the trends of LRYGB among different races from 2002 to 2008. However, this difference in the two procedures declined to the point that they were performed in almost equal proportions in Native Hawaiian or other Pacific Islander patients.

We have also demonstrated significant variation in obesity-related comorbidities among racial groups in this study population. American Indian or Alaska Native patients had the highest rate of diabetes (35.8%), while African Americans had the highest rates of hypertension (53.6%). These findings are comparable with those from the National Diabetes Statistics Report \[[@CR27]\] and National Center for Health Statistics (NCHS) data brief on hypertension \[[@CR28]\] by CDC in 2017, respectively.

Despite being the largest bariatric-specific dataset in the country with over 95% 30-day patient follow-up rate, MBSAQIP database is associated with a number of limitations. First, we were only able to test the variables that were presented in the database. For instance, factors that have been shown to affect patient outcomes such as socio-economic and insurance status, center volume, and surgeon experience are not included in the database \[[@CR19], [@CR29], [@CR30]\]. Second, the retrospective nature of the study precludes randomization of study groups; as a result, many of the variables differed significantly among racial groups and adjusting was required in the final analyses.

Conclusion {#Sec9}
==========

Postoperative complications, readmission, re-intervention, and reoperation are generally uncommon events within 30 days of bariatric surgery with 6, 3.8, 1.3, and 1.2% prevalence respectively in those who underwent LRYGB or LSG captured in 2016 MBSAQIP PUF. However, these events occur disproportionately among different races. This study is one of the first to include other racial groups besides African American and White and report racial disparity in short-term postoperative outcomes of metabolic and bariatric procedures using 2016 MBSAQIP database. Knowing which racial groups are at risk for poorer outcomes can guide perioperative measures aimed at risk reduction. Lastly, the findings presented herein should provoke future studies on the etiology of these disparities as well as strategies by which they can be meaningfully addressed.
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